FDA Approves Curium's Bexlutry, First Generic Radioligand, Challenging Lutathera's GEP-NET Monopoly
核心洞察
The FDA approved Curium (搜索)'s Bexlutry (搜索) (lutetium Lu 177 dotatate (搜索)), the first generic radioligand therapy, for adults with somatostatin receptor (搜索)-positive gastroenteropancreatic neuroendocrine tumors (搜索).
Bexlutry (搜索) was cleared via the 505(b)(2) pathway as a radioligand equivalent to Novartis' Lutathera, relying on published evidence and bridging data rather than a new pivotal trial.
The approval follows Curium (搜索)'s June 2026 patent litigation victory over Novartis subsidiary Advanced Accelerator Applications, clearing the path for immediate launch.
The U.S. Food and Drug Administration has approved Bexlutry (搜索) (lutetium Lu 177 dotatate (搜索)), a radioligand therapy from Boston-based Curium (搜索), for the treatment of adults with somatostatin receptor (搜索)-positive gastroenteropancreatic neuroendocrine tumors (搜索) (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. The clearance, granted via the 505(b)(2) pathway, marks the first generic radioligand therapy for cancer and introduces a competitor to Novartis' Lutathera (lutetium Lu 177 dotatate), which has held the only approved lutetium dotatate product in this indication since 2018.
Curium (搜索) said the product is immediately available for prescribing, and called Bexlutry (搜索) the first radioligand equivalent approved for GEP-NETs in adults. The company submitted its application in July 2024 under the 505(b)(2) pathway, which allows a sponsor to rely partly on existing data, and said it designed its formulation to avoid infringing patents listed with the FDA.
A Copycat Built on Bridging Data, Not a New Trial
Bexlutry (搜索) was approved as a radioligand equivalent to Lutathera, supported by published evidence and targeted bridging data that Curium (搜索) said demonstrated a similar biological and chemical profile to the reference product. No separate pivotal trial was conducted for Bexlutry itself; the 505(b)(2) pathway allowed reliance on the established evidence base for the reference product.
The clinical evidence cited in Bexlutry (搜索)'s labeling draws on two studies conducted with lutetium Lu 177 dotatate (搜索): the Phase III NETTER-1 trial, which evaluated the agent in patients with midgut NETs and demonstrated progression-free survival benefit versus high-dose long-acting octreotide, and the ERASMUS expanded access study, which provided long-term safety data across a broader GEP-NET population.
In ERASMUS, which began as an expanded-access program at a single site in the Netherlands, 1,214 patients were treated, of whom 360 had GEP-NETs and long-term follow-up. In that group, 17 percent had tumors shrink enough to count as a response, including three complete responses, and responses lasted a median of 35 months. A drug-specific protocol written after the study began did not set a sample size or a plan for testing hypotheses. The evidence is single-arm and largely retrospective.
NETTER-1, a randomized trial of 229 patients with advanced midgut tumors, found that lutetium Lu 177 dotatate (搜索) plus long-acting octreotide cut the risk of disease progression or death by 79 percent compared with high-dose octreotide alone. The trial's final analysis found no statistically significant difference in overall survival between the two groups.
Mechanism, Dosing and Administration
Many neuroendocrine tumors carry somatostatin receptors on their surface. Lutetium Lu 177 dotatate (搜索) binds to those receptors and is taken into the cells, where radiation from lutetium-177 damages receptor-positive cells and nearby cells, aiming radiation mainly at tumors rather than spreading it evenly through the body. The mechanism is identical to that of Lutathera.
Eligibility depends on confirming that a tumor carries these receptors, usually done with specialized imaging. The label's recommended dose is 7.4 GBq (200 mCi) every eight weeks, give or take a week, for a total of four doses, for a recommended cumulative dose of 29.6 GBq. Patients receive an amino acid infusion before, during, and after each dose to lower the radiation dose to the kidneys, along with anti-nausea medicine and long-acting octreotide injections on a set schedule. Treatment is given by health care providers trained and licensed to handle radioactive drugs.
The label says long-acting somatostatin analogs must be stopped at least four weeks before each dose and short-acting octreotide at least 24 hours before. Bexlutry (搜索) is labeled for adults only; Lutathera's label also includes pediatric use information, and Bexlutry's prescribing information says that information is left off because of the original maker's marketing exclusivity rights.
Safety Profile and Label Warnings
The label carries serious warnings. Bexlutry (搜索) adds to lifetime radiation exposure, which is linked to a higher cancer risk, and radiation can be detected in urine for up to 30 days, so patients receive instructions to protect household members.
In NETTER-1, anemia occurred in 81 percent of patients receiving the drug with octreotide and low platelet counts in 53 percent, though severe cases were rare. Myelodysplastic syndrome (搜索), a bone marrow disorder, developed in 2.3 percent of NETTER-1 patients who received the drug, over a median follow-up of 76 months. In ERASMUS, 2 percent developed myelodysplastic syndrome and 0.5 percent developed acute leukemia (搜索). Kidney failure, liver injury, allergic reactions including angioedema, and hormone surges causing flushing, diarrhea, and low blood pressure were also reported.
The drug can harm a fetus and may cause infertility. The label advises women who could become pregnant to use effective birth control during treatment and for seven months after the last dose, and men with female partners who could become pregnant to do so for four months. It also advises against breastfeeding during treatment and for 2.5 months after the last dose. Patients must be monitored for at least two hours after each infusion for signs of a severe allergic reaction, in a setting equipped for resuscitation.
Patent Fight and Corporate Consolidation
The approval follows Curium (搜索)'s June 2026 patent litigation victory over Novartis subsidiary Advanced Accelerator Applications, in which a Delaware federal court ruled all relevant patent claims invalid and not infringed. That ruling cleared the regulatory and commercial path for Bexlutry (搜索)'s launch.
Curium (搜索) has also agreed to merge with Lantheus (搜索) in a transaction valued at up to approximately USD 8 billion, potentially further expanding the combined company's radiopharmaceutical development, manufacturing, and distribution capabilities.
What the Approval Does and Does Not Change
Curium (搜索) says GEP-NETs account for 60 to 70 percent of all neuroendocrine tumors, which arise from specialized cells found throughout the body's organs. When the FDA approved Lutathera on January 26, 2018, Dr. Richard Pazdur, director of the agency's Oncology Center of Excellence, said, "GEP-NETs are a rare group of cancers with limited treatment options after initial therapy fails to keep the cancer from growing."
For patients and families, a second approved product could give treatment centers another supply option for a therapy that depends on tightly scheduled delivery. It does not change who qualifies, and it adds no new evidence that the treatment works better. Curium (搜索)'s announcement did not include a price, and the company said its priority now is a high-quality launch with consistent delivery and scheduling support for treatment sites. Whether a second supplier improves access or lowers costs will become clear only as centers begin using it.
Patients whose doctors recommend radioligand therapy can ask whether their insurer covers both products, whether prior authorization is required, and which version the treatment center uses. Other useful questions include how many doses are planned, how blood counts and kidney and liver function will be monitored, and what radiation precautions apply at home. Patients who develop signs of infection, unusual bleeding or bruising, or signs of kidney or liver problems after treatment should contact their care team promptly.